GenMark Diagnostics (GNMK) Earns Daily Media Impact Score of 0.06
Headlines about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. GenMark Diagnostics earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 45.6989754133095 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Analysts Anticipate GenMark Diagnostics, Inc. (GNMK) Will Post Quarterly Sales of $14.81 Million (americanbankingnews.com)
- Zacks: Brokerages Anticipate GenMark Diagnostics, Inc. (NASDAQ:GNMK) Will Post Earnings of -$0.27 Per Share (americanbankingnews.com)
- GenMark Diagnostics, Inc. (GNMK) Insider Sells $16,827.57 in Stock (americanbankingnews.com)
- GenMark Diagnostics, Inc. (GNMK) Forecasted to Earn FY2017 Earnings of ($1.12) Per Share (americanbankingnews.com)
- Edited Transcript of GNMK earnings conference call or presentation 1-Aug-17 12:30pm GMT (finance.yahoo.com)
Several equities research analysts have weighed in on GNMK shares. Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of GenMark Diagnostics in a research note on Sunday, April 23rd. BidaskClub upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded GenMark Diagnostics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, April 11th. Canaccord Genuity restated a “buy” rating and set a $17.00 target price on shares of GenMark Diagnostics in a research note on Monday, June 12th. Finally, Cowen and Company restated an “outperform” rating and set a $17.00 target price on shares of GenMark Diagnostics in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $15.80.
GenMark Diagnostics (GNMK) traded down 1.81% during midday trading on Monday, reaching $10.84. The company’s stock had a trading volume of 339,725 shares. The company’s market cap is $592.59 million. GenMark Diagnostics has a 12 month low of $8.03 and a 12 month high of $13.67. The stock has a 50-day moving average price of $11.92 and a 200 day moving average price of $12.31.
GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.05. The firm had revenue of $12.36 million for the quarter, compared to analysts’ expectations of $12.44 million. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.30) earnings per share. Analysts expect that GenMark Diagnostics will post ($1.03) earnings per share for the current fiscal year.
In related news, CFO Scott Mendel sold 2,135 shares of the company’s stock in a transaction on Friday, May 19th. The shares were sold at an average price of $12.89, for a total value of $27,520.15. Following the completion of the transaction, the chief financial officer now directly owns 143,079 shares in the company, valued at $1,844,288.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Hany Massarany sold 8,239 shares of the company’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $12.89, for a total transaction of $106,200.71. The disclosure for this sale can be found here. Insiders sold 16,015 shares of company stock valued at $201,742 over the last quarter. 7.50% of the stock is owned by company insiders.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.